Catabasis Pharmaceuticals Inc (NASDAQ: CATB) shares were up significantly, on March 10, 2017, CATB was up 53.38% at the close. Markets participants exchanged 59,565,706 shares, over 20.36 times the 30-day average daily trading volume. CATB had a high degree of volatility, trading between $1.08 and $7.89, over the past 52-weeks, as of March 10, 2017.
That said, CATB was up over 80%, over the past five trading days, outperforming the industry by 81.08%. Additionally, Catabasis Pharmaceuticals Inc was up 67.21%, while the biotechnology industry has been up just 5.88% over the past month.
Here’s a look at Catabasis Pharmaceuticals Inc:
Catabasis Pharmaceuticals Inc is a clinical-stage biopharma company and aims to bring life-changing and hopeful therapies to patients and families. The company’s Safely Metabolized And Rationally Targeted (SMART) linker drug discovery platform allows the company to engineer molecules to simultaneously modulate multiple targets in a disease.
Catabasis Pharmaceuticals Stats and Info
Take a look at some statistics on Catabasis Pharmaceuticals Inc that you might find useful:
– Catabasis Pharmaceuticals Inc had a market cap of $58,363,479, as of March 10, 2017.
– The stock had 28,609,549 shares outstanding and a short interest of 893,779 shares, or 3.12% shares short.
– CATB had a trailing 12-month EPS of $-2.40, and it did not have any revenue over this period.
– Catabasis Pharmaceuticals Inc reported total liabilities of $12,079,000 and total equity of $36,861,000 in its recent financial statements.
– The company had a debt-to-equity ratio of 8.75%, indicating CATB has not been taking on too much debt.
– Catabasis Pharmaceuticals Inc is expected to report its earnings on March 16, 2017 at 5:55 PM ET, and analysts are expecting an earnings loss of $0.49 per share.
Potential Catalysts for Catabasis Pharmaceuticals
Here are the potential catalyst that pushed Catabasis Pharmaceuticals Inc shares higher today. CATB did not release any exciting information that would warrant over a 50% rise in one day. However, the company presented at Cowen and Company 37th Annual Health Care Conference, and showed its robust clinical and preclinical product candidates pipeline. Moreover, it will present some more data next week.
Catabasis Pharmaceuticals announced it would present data from Part B of the MoveDMD trial of edasalonexent (CAT-1004) for the treatment of Duchenne muscular dystrophy (DMD) at the 2017 Muscular Dystrophy Association Scientific Conference, which is expected to be held between March 19 and March 22, 2017, in Arlington, VA, at the Hyatt Regency Crystal City.
That said, Catabasis Pharmaceuticals Chief Medical Officer Joanne Donovan, M.D., Ph.D., is expected to deliver both poster and oral presentations entitled “MoveDMD: Phase 1/2 trial of Edasalonexent, an NF-kB Inhibitor, in 4- to 7-Year-Old Patients with Duchenne Muscular Dystrophy.”
Edasalonexent (CAT-1004) is an investigational oral small molecule, currently being developed as a potential disease-modifying therapy for all patients affected by Duchenne muscular dystrophy (DMD or Duchenne), regardless of the underlying mutation.
The U.S. Food and Drug Administration (FDA) granted Edasalonexent (CAT-1004) orphan drug, fast track and rare pediatric disease designations. Additionally, the European commission granted orphan medicinal product designation for the treatment of DMD.
The Bottom Line
That said, traders and market participants may be buying into the company’s earnings this week. Consequently, they may be expecting the company to beat analyst estimates. Moreover, traders may be placing their bets on Catabasis Pharmaceuticals potentially releasing strong results in its Part B of the MoveDMD trial of edasalonexent. Keep in mind, this would be considered a high risk, high potential reward.